migraine Archives -

AbbVie has submitted its oral CGRP inhibitor atogepant for prevention of both episodic and chronic migraine in the

Chasing rivals, AbbVie files migraine prevention drug atogepant in EU

https://pharmaphorum.com/news/chasing-rivals-abbvie-files-migraine-prevention-drug-atogepant-in-eu/

News/ News/ Sales and Marketing

AbbVie files Qulipta for chronic migraine prevention

Phil Taylor AbbVie, Biohaven Pharmaceuticals, migraine, Nurtec ODT, Pfizer, prevention, Qulipta 0 Comment

AbbVie has filed for approval of its oral CGRP inhibitor Qulipta for prevention of chronic migraine, seeking to

AbbVie files Qulipta for chronic migraine prevention

https://pharmaphorum.com/news/abbvie-files-qulipta-for-chronic-migraine-prevention/

News/ News/ Sales and Marketing

Pfizer upgrades Biohaven alliance to a takeover bid

Phil Taylor Biohaven Pharmaceuticals, CGRP, M&A, migraine, Pfizer 0 Comment

Not content with a $1.2 billion licensing deal for Biohaven Pharma’s oral migraine therapy rimegepant, Pfizer has just

Pfizer upgrades Biohaven alliance to a takeover bid

https://pharmaphorum.com/news/pfizer-upgrades-biohaven-alliance-to-a-takeover-bid/

Market Access/ News/ News/ News/ Sales and Marketing

Pfizer/Biohaven migraine drug rimegepant gets EU green light

Phil Taylor AbbVie, Biohaven Pharmaceuticals, CGRP, migraine, Pfizer, Qulipta, Vydura 0 Comment

Pfizer’s $1.2 billion licensing deal with Biohaven for rights to oral migraine drug rimegepant is approaching a payoff

Pfizer/Biohaven migraine drug rimegepant gets EU green light

https://pharmaphorum.com/news/pfizer-biohaven-migraine-drug-rimegepant-gets-eu-green-light/

News/ News/ R&D

AbbVie sees bigger role for Qulipta in migraine prevention

Phil Taylor AbbVie, Biohaven Pharmaceuticals, chronic migraine, migraine, prevention, Qulipta 0 Comment

AbbVie’s Qulipta has become the first oral drug in the CGRP inhibitor class to show efficacy in chronic

AbbVie sees bigger role for Qulipta in migraine prevention

https://pharmaphorum.com/news/abbvie-sees-bigger-role-for-qulipta-in-migraine-prevention/

Digital/ News/ News

Ex-CoverMyMeds CEO Scantland launches new digital health project

Phil Taylor AndHealth, CoverMyMeds, digital, digital health, McKesson, migraine 0 Comment

Five years after selling CoverMyMeds to McKesson for $1.4 billion, the company’s CEO Matt Scantland has returned to

Ex-CoverMyMeds CEO Scantland launches new digital health project

https://pharmaphorum.com/news/ex-covermymeds-ceo-scantland-launches-new-digital-health-project/

News/ News/ R&D

Amid crowded migraine market, Lundbeck goes its own way

Phil Taylor CGRP, Lundbeck, migraine, PACAP, Vyepti 0 Comment

The market for migraine treatment and prevention has been transformed by the launch of several new drugs targeting

Amid crowded migraine market, Lundbeck goes its own way

https://pharmaphorum.com/news/amid-crowded-migraine-market-lundbeck-goes-its-own-way/

News/ News/ Sales and Marketing

Pfizer strikes $1.2bn licensing deal for Biohaven migraine drug

Phil Taylor Biohaven Pharmaceuticals, central nervous system, CGRP, migraine, partnering, Pfizer 0 Comment

Pfizer has bolstered its central nervous system (CNS) drugs portfolio with a $1.2 billion deal to claim rights

Pfizer strikes $1.2bn licensing deal for Biohaven migraine drug

https://pharmaphorum.com/news/pfizer-strikes-1-2bn-licensing-deal-for-biohaven-migraine-drug/

Market Access/ News/ News

AbbVie’s Qulipta cleared for migraine prevention, setting up Biohaven clash

Phil Taylor AbbVie, Biohaven Pharmaceuticals, CGRP, migraine, prevention, Qulipta 0 Comment

AbbVie has added a third drug to its arsenal in the crowded migraine market, getting FDA approval for

AbbVie’s Qulipta cleared for migraine prevention, setting up Biohaven clash

https://pharmaphorum.com/news/abbvies-qulipta-cleared-for-migraine-prevention-setting-up-biohaven-clash/

Trending

migraine

Login